Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) have received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target […]
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) shares were down 2.7% during mid-day trading on Friday . The company traded as low as $25.10 and last traded at $25.59. Approximately 347,433 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 904,115 shares. The stock had previously closed at […]
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) CFO James M. Frates sold 32,500 shares of the business’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $26.94, for a total value of $875,550.00. Following the completion of the transaction, the chief financial officer now owns 55,676 shares […]
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) insider Patrick D. Yeramian sold 11,965 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $29.03, for a total value of $347,343.95. Following the transaction, the insider now directly owns 208,417 shares in the […]
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 6,870,000 shares, an increase of 12.6% from the April 15th total of 6,100,000 shares. Currently, 16.0% of the shares of the company are short sold. Based on […]